Novo Nordisk strategy in obesity and diabetes, shares extend strong Copenhagen run

Novo Nordisk leans on its obesity and diabetes franchise as analysts such as Berenberg and Deutsche Bank update their views and Nasdaq Copenhagen trading shows a firm share price near 300 Danish kroner.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 20:33.

Novo Nordisk (DK0062498333) remains firmly anchored on Nasdaq Copenhagen, with the B shares changing hands around 300 Danish kroner on June 22 according to exchange data. The group continues to be a heavyweight in global diabetes and obesity care, drawing intense analyst and investor attention in Europe and the United States.

What recent analyst notes show

On June 19, Deutsche Bank reiterated its Hold rating on Novo Nordisk with a price target of 290 Danish kroner, underscoring a more cautious stance after the strong rally in the shares on Nasdaq Copenhagen. MarketScreener summary of analyst actions Berenberg, by contrast, raised its target to 325 Danish kroner and maintained a Buy recommendation, citing robust expected growth from obesity drug Wegovy and the broader GLP-1 portfolio. Analyst recap including Berenberg and Nordea

Nordea Bank also published a Buy rating in mid-June, reinforcing a generally positive sell-side bias despite the Deutsche Bank Hold call and the already high valuation metrics relative to traditional large-cap European pharma peers such as Eli Lilly and Sanofi. Nordea Bank rating overview Consensus data compiled by MarketScreener show Novo Nordisk trading at a significant earnings multiple premium, reflecting expectations for durable GLP-1 demand.

Long-term strategy in obesity and diabetes

Novo Nordisk’s strategic focus remains centered on diabetes care and obesity treatments, supported by substantial reinvestment in research and development and targeted manufacturing expansion in Europe and the United States. Novo Nordisk Investor Relations overview The Novo Nordisk Foundation recently announced a 450 million Danish kroner investment in cardiometabolic drug discovery, highlighting the broader ecosystem backing for future pipeline growth around metabolic diseases. Report on Novo Nordisk Foundation initiative

In addition to obesity drug Wegovy and diabetes brands such as Ozempic, the company invests in next-generation oral formulations that aim to make GLP-1 therapies more convenient and scalable. This strategy positions Novo Nordisk against global peers including Eli Lilly, which is expanding its own obesity and diabetes franchises, in a market expected to reach tens of billions of dollars annually over the coming years.

The product behind the stock

A flagship product in the Novo Nordisk portfolio is Wegovy, a once-weekly injectable semaglutide formulation approved for chronic weight management in several major markets. The company also markets Ozempic for type 2 diabetes and a broad range of insulin and GLP-1 therapies that together anchor its revenue base.

Where the stock trades today

The Novo Nordisk shares (DK0062498333) traded on June 22, 2026 at around 299.95 Danish kroner on Nasdaq Copenhagen, based on data from the official Copenhagen listing and consolidated market services.

Key data on the Novo Nordisk shares

• Company: Novo Nordisk A/S
• ISIN: DK0062498333
• WKN: A3EU6F
• Ticker: NOVO-B (Copenhagen), NVO (NYSE ADR)
• Trading venue: Nasdaq Copenhagen
• Price (as of 2026-06-22, 20:17): 299.95 DKK
• Market cap: 993.14 billion DKK (as of 2026-06-22)
• Sector / industry: Health care / Pharmaceuticals & Biotechnology
• Index membership: OMX Copenhagen 25, Stoxx Europe 600
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell any securities. All data are based on sources believed to be reliable, but their accuracy cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.